Download PDF
Semin Thromb Hemost 2024; 50(02): 284-287
DOI: 10.1055/s-0043-1771268
Commentary

Are Antiphospholipid Antibodies a Surrogate Risk Factor for Thrombosis in Sepsis?

Jecko Thachil 
1   Department of Haematology, Manchester University Hospitals, Manchester, United Kingdom
,
Emmanuel J. Favaloro 
2   Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia
3   Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia
4   Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia
5   School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia
,
Giuseppe Lippi 
6   Section of Clinical Biochemistry, University of Verona, Verona, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Antiphospholipid syndrome (APS) is a hypercoagulable state caused by antiphospholipid antibodies (aPL). APS clinically manifests with arterial or venous or microvascular thrombi and/or pregnancy complications. It is well-known that the development of aPL can be a transient phenomenon and thus the current diagnostic criterion for APS requires repeat laboratory testing several weeks apart before a definitive diagnosis is made. However, transient presence of aPL may also be pathogenic. In this article, we attempt to give historical and clinical evidence for the importance of these antibodies, even when transient, and call for further research into mechanisms by which these antibodies may promote thrombosis and pregnancy morbidities.

Keywords

antiphospholipid - lupus anticoagulant - pregnancy - sepsis - thromboembolism


Publication History

Article published online:
28 July 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Maneta E, Aivalioti E, Tual-Chalot S. et al. Endothelial dysfunction and immunothrombosis in sepsis. Front Immunol 2023; 14: 1144229
    CrossrefPubMedGoogle Scholar
  • 2 Knight JS, Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol 2022; 44 (03) 347-362
    CrossrefPubMedGoogle Scholar
  • 3 Sciascia S, Radin M, Bazzan M. et al. Antiphospholipid antibodies and infection: non nova sed nove . Front Immunol 2021; 12: 687534
    CrossrefPubMedGoogle Scholar
  • 4 Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31 (04) 256-263
    CrossrefPubMedGoogle Scholar
  • 5 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11) 2828-2839
    CrossrefPubMedGoogle Scholar
  • 6 Devreese KMJ, Ortel TL, Pengo V, de Laat B. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (04) 809-813
    CrossrefPubMedGoogle Scholar
  • 7 Jayakody Arachchillage D, Greaves M. The chequered history of the antiphospholipid syndrome. Br J Haematol 2014; 165 (05) 609-617
    CrossrefPubMedGoogle Scholar
  • 8 Asherson R, Cervera R, Piette JC. et al. The Antiphospholipid Syndrome: History, Definition, Classification and Differential Diagnosis in the Antiphospholipid Syndrome. Boca Raton, Florida, United States: CRC Press; 1996: 3-12
    Google Scholar
  • 9 Pagborn MC. A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 1941; 44: 484-486
    CrossrefPubMedGoogle Scholar
  • 10 Harris A, Riedel LM, Riedel LM. A microflocculation test for syphilis using cardiolipin antigen; preliminary report. J Vener Dis Inf 1946; 27 (07) 169-174
    PubMedGoogle Scholar
  • 11 Moore JE, Mohr CF. Biologically false positive serologic tests for syphilis; type, incidence, and cause. J Am Med Assoc 1952; 150 (05) 467-473
    CrossrefPubMedGoogle Scholar
  • 12 Lubinski HH. Interpretation and significance of false positive serological reactions for syphilis. Can Med Assoc J 1947; 57: 33-35
    PubMedGoogle Scholar
  • 13 Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003; 62 (05) 388-393
    CrossrefPubMedGoogle Scholar
  • 14 Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res 2012; 129 (03) 290-295
    CrossrefPubMedGoogle Scholar
  • 15 Rodríguez-Pintó I, Moitinho M, Santacreu I. et al; CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev 2016; 15 (12) 1120-1124
    CrossrefPubMedGoogle Scholar
  • 16 Fischetti F, Durigutto P, Pellis V. et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106 (07) 2340-2346
    CrossrefPubMedGoogle Scholar
  • 17 Jankowski M, Vreys I, Wittevrongel C. et al. Thrombogenicity of β 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101 (01) 157-162
    CrossrefPubMedGoogle Scholar
  • 18 Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7 (06) 330-339
    CrossrefPubMedGoogle Scholar
  • 19 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368 (11) 1033-1044
    CrossrefPubMedGoogle Scholar
  • 20 Bowles L, Platton S, Yartey N. et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med 2020; 383 (03) 288-290
    CrossrefPubMedGoogle Scholar
  • 21 Zhang Y, Xiao M, Zhang S. et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med 2020; 382 (17) e38
    CrossrefPubMedGoogle Scholar
  • 22 Helms J, Tacquard C, Severac F. et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46 (06) 1089-1098
    CrossrefPubMedGoogle Scholar
  • 23 Foret T, Dufrost V, Salomon Du Mont L. et al. Systematic review of antiphospholipid antibodies in COVID-19 patients: culprits or bystanders?. Curr Rheumatol Rep 2021; 23 (08) 65
    CrossrefPubMedGoogle Scholar
  • 24 Constans M, Santiago R, Jimenez L. et al. Lupus anticoagulant is an independent risk factor for non-thrombotic in-hospital mortality in COVID-19 patients. Thromb Res 2021; 208: 99-105
    CrossrefPubMedGoogle Scholar
  • 25 Pineton de Chambrun M, Frere C, Miyara M. et al. High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?. J Intern Med 2021; 289 (03) 422-424
    CrossrefPubMedGoogle Scholar
  • 26 Siguret V, Voicu S, Neuwirth M. et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?. Thromb Res 2020; 195: 74-76
    CrossrefPubMedGoogle Scholar
  • 27 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: time for a reality check?. Semin Thromb Hemost 2022; 48 (01) 72-92
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Zuo Y, Estes SK, Ali RA. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020; 12 (570) eabd3876
    CrossrefPubMedGoogle Scholar
  • 30 Hollerbach A, Müller-Calleja N, Pedrosa D. et al. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J Thromb Haemost 2021; 19 (09) 2335-2347
    CrossrefPubMedGoogle Scholar
  • 31 Minassian C, Thomas SL, Williams DJ, Campbell O, Smeeth L. Acute maternal infection and risk of pre-eclampsia: a population-based case-control study. PLoS One 2013; 8 (09) e73047
    CrossrefPubMedGoogle Scholar
  • 32 Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2008; 198 (01) 7-22
    CrossrefPubMedGoogle Scholar
  • 33 Yan L, Jin Y, Hang H, Yan B. The association between urinary tract infection during pregnancy and preeclampsia: a meta-analysis. Medicine (Baltimore) 2018; 97 (36) e12192
    CrossrefPubMedGoogle Scholar
  • 34 De Carolis S, Botta A, Santucci S. et al. Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allergy Immunol 2010; 38 (2-3): 116-124
    CrossrefPubMedGoogle Scholar
  • 35 De Carolis S, Caruso A, Ferrazzani S, Carducci B, De Santis L, Mancuso S. Poor pregnancy outcome and anticardiolipin antibodies. Fetal Diagn Ther 1994; 9 (05) 296-299
    CrossrefPubMedGoogle Scholar
  • 36 Simchen MJ, Goldstein G, Lubetsky A, Strauss T, Schiff E, Kenet G. Factor v Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke 2009; 40 (01) 65-70
    CrossrefPubMedGoogle Scholar
  • 37 Herrera CA, Heuser CC, Branch DW. Stillbirth: the impact of antiphospholipid syndrome?. Lupus 2017; 26 (03) 237-239
    CrossrefPubMedGoogle Scholar